Brokerages expect Endo International plc – (NASDAQ:ENDP) (TSE:ENL) to report earnings per share (EPS) of $0.54 for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Endo International’s earnings. The lowest EPS estimate is $0.50 and the highest is $0.60. Endo International reported earnings per share of $1.23 in the same quarter last year, which indicates a negative year-over-year growth rate of 56.1%. The business is scheduled to report its next quarterly earnings results on Tuesday, May 8th.
On average, analysts expect that Endo International will report full-year earnings of $2.36 per share for the current financial year, with EPS estimates ranging from $2.21 to $2.80. For the next fiscal year, analysts expect that the company will report earnings of $2.46 per share, with EPS estimates ranging from $1.45 to $2.95. Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for Endo International.
Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its quarterly earnings results on Tuesday, February 27th. The company reported $0.77 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.15. Endo International had a positive return on equity of 81.03% and a negative net margin of 58.68%. The firm had revenue of $768.64 million for the quarter, compared to analyst estimates of $762.29 million. During the same period in the previous year, the firm earned $1.77 earnings per share. The company’s revenue was down 38.1% compared to the same quarter last year.
Several institutional investors and hedge funds have recently modified their holdings of ENDP. Quantitative Investment Management LLC bought a new stake in shares of Endo International in the fourth quarter worth $1,569,000. Van ECK Associates Corp grew its holdings in shares of Endo International by 67.1% in the third quarter. Van ECK Associates Corp now owns 340,991 shares of the company’s stock worth $2,921,000 after acquiring an additional 136,873 shares during the period. River & Mercantile Asset Management LLP grew its holdings in shares of Endo International by 32.7% in the fourth quarter. River & Mercantile Asset Management LLP now owns 475,650 shares of the company’s stock worth $3,679,000 after acquiring an additional 117,110 shares during the period. Amundi Pioneer Asset Management Inc. grew its holdings in shares of Endo International by 235.6% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 96,033 shares of the company’s stock worth $745,000 after acquiring an additional 67,415 shares during the period. Finally, Alps Advisors Inc. grew its holdings in shares of Endo International by 22.9% in the fourth quarter. Alps Advisors Inc. now owns 307,839 shares of the company’s stock worth $2,386,000 after acquiring an additional 57,328 shares during the period. 96.54% of the stock is owned by institutional investors.
Shares of Endo International (NASDAQ:ENDP) traded up $0.07 on Friday, reaching $7.08. The company’s stock had a trading volume of 1,384,014 shares, compared to its average volume of 5,953,839. Endo International has a 12-month low of $5.77 and a 12-month high of $14.15. The company has a debt-to-equity ratio of 17.00, a quick ratio of 0.85 and a current ratio of 1.02. The firm has a market capitalization of $1,567.85, a price-to-earnings ratio of -0.78 and a beta of 0.35.
ILLEGAL ACTIVITY NOTICE: “Endo International plc – (ENDP) Expected to Announce Earnings of $0.54 Per Share” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/3261763/endo-international-plc-endp-expected-to-announce-earnings-of-0-54-per-share.html.
About Endo International
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.